Dasatinib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally once daily (100 mg once daily for chronic phase; 140 mg once daily for advanced phase/blast crisis) with or without food. Swallow tablets whole; do NOT crush, split, or chew. Avoid taking antacids within 2 hours of dasatinib (gastric acid suppression reduces bioavailability).
⚠️ Side Effects
Common: Pleural effusion (occurs in up to 15-30% of patients), dyspnea, fluid retention, diarrhea, headache, musculoskeletal pain, fatigue. Rare/Severe: Severe myelosuppression, pulmonary arterial hypertension (PAH), severe gastrointestinal hemorrhage, and QT interval prolongation.
🛡️ Safety Warnings
Black Box Warning: Myelosuppression (severe neutropenia, thrombocytopenia) and bleeding events. Monitor for dry cough, dyspnea, and pleuritic chest pain; pleural effusion often requires temporary drug interruption and diuretic/corticosteroid therapy. Screen for pulmonary arterial hypertension if persistent dyspnea develops. Avoid H2 blockers and PPIs.
Jan Aushadhi Products containing Dasatinib
Found 4 generic formulation(s) containing this active ingredient.
Dasatinib 50mg Tablets
Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.
Dasatinib Tablets 20mg
Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.
Dasatinib Tablets 50mg
Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.
Dasatinib Tablets 70mg
Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Dasatinib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Dasatinib 50mg Tablets | 60's Bottle | ₹1031.25 | DASAPAN, BEEDAN, SPNIB, DYRONIB, DASAMYL | ₹5688.29 | 82% Save |
| Dasatinib Tablets 20mg | 60's Bottle in Monopack | ₹1204.69 | DASH, SPNIB, DASASHIL, BEEDAN | ₹2287.52 | 47% Save |
| Dasatinib Tablets 50mg | 60's Bottle in Monopack | ₹2217.19 | DASAPAN, BEEDAN, SPNIB, DYRONIB, DASAMYL | ₹5688.29 | 61% Save |
| Dasatinib Tablets 70mg | 60's Bottle in Monopack | ₹2811.56 | DASH, SPNIB, BEEDAN, DASAPAN | ₹6020.89 | 53% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Dasatinib generics.